Altimmune Inc (STU:3G0) Stock News, Headlines & Updates
Altimmune Inc Stock News from GuruFocus
- 1
- 2
Jul 23, 2025
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Altimmune, Inc. - ALT
Marketwired • 9:00am
Jul 22, 2025
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Altimmune, Inc. - ALT
PRNewswire • 10:00am
Jul 19, 2025
ALT Investors Have Opportunity to Join Altimmune, Inc. Fraud Investigation with the Schall Law Firm
Business Wire • 2:00pm
Jul 18, 2025
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Altimmune, Inc. - ALT
Marketwired • 11:00am
Jul 17, 2025
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Altimmune, Inc. - ALT
PRNewswire • 10:00am
Jul 14, 2025
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of Altimmune, Inc. - ALT
Marketwired • 9:00am
Jul 10, 2025
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Altimmune, Inc. - ALT
Marketwired • 9:00am
Altimmune (ALT) Target Price Lowered by JMP Securities | ALT Stock News
GuruFocus News • 8:35am
Altimmune (ALT) Faces Price Target Reduction Amid Challenges | ALT Stock News
GuruFocus News • 4:45am
Goldman Sachs Issues Sell Rating for Altimmune (ALT) with Price Target of $1 | ALT Stock News
GuruFocus News • 4:16am
Jul 09, 2025
Altimmune Announces Initiation of RESTORE Phase 2 Trial Evaluating the Efficacy and Safety of Pemvidutide in Alcohol-Associated Liver Disease (ALD)
Marketwired • 7:00am
Altimmune (ALT) Kicks Off Restore Phase 2 Trial for Liver Disease Treatment | ALT Stock News
GuruFocus News • 6:48am
Altimmune Announces Initiation of RESTORE Phase 2 Trial Evaluating the Efficacy and Safety of Pemvidutide in Alcohol-Associated Liver Disease (ALD) | ALT Stock News
GuruFocus News • 6:47am
Jul 07, 2025
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Altimmune, Inc. - ALT
PRNewswire • 3:00pm
Jul 03, 2025
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Altimmune, Inc. - ALT
Marketwired • 9:00am
Jul 02, 2025
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Altimmune, Inc. - ALT
PRNewswire • 10:00am
Jul 01, 2025
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Altimmune, Inc. - ALT
Marketwired • 10:00am
Jun 28, 2025
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Altimmune, Inc. - ALT
Marketwired • 10:00am
Jun 27, 2025
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Altimmune, Inc. - ALT
PRNewswire • 3:00pm
Altimmune (ALT) Stock Decline Seen as Excessive by Jefferies | ALT Stock News
GuruFocus News • 2:45pm
Altimmune (ALT) Receives Reiterated "Buy" Rating from HC Wainwright & Co. | ALT Stock News
GuruFocus News • 5:30am
Jun 26, 2025
Altimmune (ALT) Stock Target Reevaluated Following Trial Results | ALT Stock News
GuruFocus News • 1:45pm
INVESTOR ALERT: Investigation of Altimmune, Inc. (ALT) Announced by Holzer & Holzer, LLC
Marketwired • 1:00pm
Altimmune (ALT) Reports Promising Phase 2b Results for Pemvidutide | ALT Stock News
GuruFocus News • 12:15pm
Altimmune (ALT) Shares Drop Despite Positive Phase 2b Trial Results | ALT Stock News
GuruFocus News • 12:00pm
Altimmune (ALT) Shares Plunge After Mixed Trial Results for MASH Therapy
GuruFocus News • 7:55am
Altimmune (ALT) Reports Promising Phase 2b Trial Results for Pemvidutide | ALT Stock News
GuruFocus News • 6:48am
Altimmune Announces Positive Topline Results from the IMPACT Phase 2b Trial of Pemvidutide in the Treatment of MASH | ALT Stock News
GuruFocus News • 6:20am
Altimmune Announces Positive Topline Results from the IMPACT Phase 2b Trial of Pemvidutide in the Treatment of MASH
Marketwired • 6:00am
Altimmune to Announce Topline 24 Week Results from its IMPACT Phase 2b Trial of Pemvidutide in the Treatment of MASH on Thursday, June 26
Marketwired • 7:00pm
Jun 25, 2025
Altimmune (ALT) to Reveal Key Data from Phase 2b Trial in Upcoming Webcast | ALT Stock News
GuruFocus News • 6:45pm
Altimmune to Announce Topline 24 Week Results from its IMPACT Phase 2b Trial of Pemvidutide in the Treatment of MASH on Thursday, June 26 | ALT Stock News
GuruFocus News • 6:30pm
Jun 13, 2025
Altimmune Announces Multiple Presentations at Upcoming American Diabetes Association's Scientific Sessions
Marketwired • 7:00am
Altimmune Announces Multiple Presentations at Upcoming American Diabetes Association's Scientific Sessions | ALT Stock News
GuruFocus News • 6:45am
May 22, 2025
ALT Hosts Virtual Meeting to Discuss Strategic Developments | ALT Stock News
GuruFocus News • 3:15pm
May 19, 2025
Altimmune Announces Initiation of RECLAIM Phase 2 Trial Evaluating the Efficacy and Safety of Pemvidutide in Alcohol Use Disorder (AUD)
Marketwired • 7:00am
Altimmune Announces Initiation of RECLAIM Phase 2 Trial Evaluating the Efficacy and Safety of Pemvidutide in Alcohol Use Disorder (AUD) | ALT Stock News
GuruFocus News • 6:46am
Altimmune (ALT) Begins Phase 2 Trial for Pemvidutide in Treating Alcohol Use Disorder | ALT Stock News
GuruFocus News • 6:46am
May 14, 2025
Altimmune to Participate at Two Upcoming Investor Conferences
Marketwired • 7:00am
Altimmune to Participate at Two Upcoming Investor Conferences | ALT Stock News
GuruFocus News • 6:52am
- 1
- 2
Show
Entries
Headlines
Total 0- 1
No recent news